SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.;JIANGSU HENGRUI MEDICINE CO., LTD.
发明人:
GU, JINMING,LUO, XIAO,TAO, WEIKANG
申请号:
CA3061791
公开号:
CA3061791A1
申请日:
2018.05.11
申请国别(地区):
CA
年份:
2019
代理人:
摘要:
The present invention provides a fusion protein containing TGF-.beta. receptorandpharmaceutical use thereof. Further, the present invention provides abifunctional fusionprotein comprising the PD-L1 antibody targeting portion and the TGF- .beta.RIIextracellulardomain, and a pharmaceutical composition comprising the fusion proteincontaining TGF-.beta.receptor, and the use thereof in the preparation of anti-cancer drug.